Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab

Abstract Background BCD-022 is a trastuzumab biosimilar which was shown to be equivalent to reference trastuzumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clinical trial was conducted to comparatively assess e...

Full description

Bibliographic Details
Main Authors:	Sergey M. Alexeev, Andrey V. Khorinko, Guzel Z. Mukhametshina, Konstantin G. Shelepen, Olga N. Burdaeva, Sergey A. Kulik, Chiradoni Thugappa Satheesh, Kirti Srivastava, Mummaneni Vikranth, Fedor Kryukov, Anastasia N. Paltusova, Mariya S. Shustova, Roman A. Ivanov
Format:	Article
Language:	English
Published:	BMC 2020-08-01
Series:	BMC Cancer
Online Access:	http://link.springer.com/article/10.1186/s12885-020-07247-9

Internet

http://link.springer.com/article/10.1186/s12885-020-07247-9

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab

Internet

Similar Items